
From left, Purdue University researchers Xiaoling Chen, Yang Yang and Jingliang Zhang study how changes in the SCN2A gene disrupt brain circuits and how restoring its function may help reverse those effects. (Purdue University photo)
Study in Neuron provides a human-cell model for studying SCN2A-related neurodevelopmental disorders and testing potential gene-based treatments
For families affected by neurodevelopmental disorders, understanding what causes a child’s symptoms is only part of the challenge. The larger question is what can be done about it.
New research from the Purdue University College of Pharmacy brings scientists one step closer to answering that question for people with disorders associated with changes in the SCN2A gene, which plays a critical role in the electrical signaling of brain cells.
The study, led by principal investigator Yang Yang, McCoy Associate Professor in the Borch Department of Medicinal Chemistry and Molecular Pharmacology (BMCMP), shows how reduced SCN2A function can disrupt communication between two interconnected regions of the human brain and, importantly, demonstrates that restoring the gene can partially reverse those abnormalities. The study published Sept. 30 in Neuron. Other lead researchers were leading co-first author Xiaoling Chen and co-first author Jingliang Zhang, both research scientists in BMCMP.
“This work gives us a strong foundation to develop and test gene-based therapies, from gene replacement to future approaches such as CRISPR genome editing, with the long-term goal of achieving more durable and potentially curative treatments,” Yang said.
SCN2A mutations are associated with autism, epilepsy and other neurodevelopmental disorders. The gene provides instructions for making a sodium channel that is essential for electrical signaling in neurons. When SCN2A function is reduced, the effects can extend beyond individual brain cells, potentially disrupting how groups of neurons communicate across brain regions.
Understanding those circuit-level changes is particularly important because neurological disorders ultimately affect people through changes in how the brain functions, influencing development, communication, behavior and other aspects of daily life.
To investigate those changes in a human system, the Purdue team developed a new model that connects two types of human brain organoids: cortical and striatal tissue. These “mini-brain” structures were grown from human cells called iPSCs that are derived from the skin tissue of donors and connected to recreate an important brain circuit in the laboratory.
The resulting human brain assembloid allowed the researchers to study how SCN2A deficiency affects communication between the cortex and striatum, two regions that work together as part of the brain’s complex network of information processing.
According to Chen, the researchers found that reducing SCN2A function unexpectedly made neurons more excitable while also disrupting connections and communication between the two brain regions.
“Our human cortico-striatal assembloid model allowed us to examine how SCN2A deficiency disrupts neuronal and circuit function in a human system,” Chen said. “Importantly, we found that restoring SCN2A could partially reverse these cellular and circuit abnormalities, highlighting the value of this model for understanding disease mechanisms and evaluating potential therapeutic strategies.”
Zhang said the model also allowed the researchers to investigate where the circuit abnormalities originated. By combining cortical and striatal tissues with different genetic backgrounds, they could determine whether changes resulted from the neurons sending signals, receiving them or both.
“One of the strengths of our approach is that we can mix and match cortical and striatal tissues with different genetic backgrounds,” Zhang said. “This allowed us to determine whether circuit abnormalities arise from the sending or receiving side of the connection, providing mechanistic insight that is difficult to obtain in conventional animal models.”
The researchers’ findings point to gene restoration as a potential strategy for correcting some of the cellular and circuit abnormalities associated with SCN2A deficiency. The next step is to further develop that approach by optimizing the dose, timing and delivery of SCN2A restoration.
Because the study suggests that the level of SCN2A expression is critical, Yang said his lab will work to identify a therapeutic window that maximizes the potential benefit while avoiding excessive gene expression. They also plan to test the strategy across additional SCN2A variants and in more advanced models to determine whether restoring SCN2A can produce sustained improvements in circuit function and disease-relevant outcomes.
This study is part of Purdue University’s One Health initiative, which involves research at the intersection of human, animal and plant health. The work was supported by the FamilieSCN2A Foundation and the National Institute of Neurological Disorders and Stroke (NINDS).



